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The synthesis and in vitro cytotoxicity of a series of RuII(arene) complexes with
carbohydrate-derived phosphite ligands and various arene co-ligands is described. The
arene ligand has a strong influence on the in vitro anticancer activity of this series of
compounds, which correlates fairly well with cellular accumulation. The most lipophilic
compound bearing a biphenyl moiety and a cyclohexylidene-protected carbohydrate is
the most cytotoxic with unprecedented IC50 values for the compound class in three
human cancer cell lines. This compound shows reactivity to the DNA model nucleobase
9-ethylguanine, but does not alter the secondary structure of plasmid DNA, indicating that
other biological targets are responsible for its cytotoxic effect.
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INTRODUCTION
In recent years, half-sandwich RuII(arene) complexes (Figure 1)
have been shown to have promising anticancer activity that is in
some cases comparable or superior to that of established anti-
cancer drugs (Dyson, 2007; Peacock and Sadler, 2008; Hartinger
and Dyson, 2009; Gasser et al., 2011; Hartinger et al., 2012). The
best investigated examples of this class are [RuII(arene)(pta)Cl2]
(RAPTA; pta = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane)
(Dyson, 2007), [RuII(arene)(en)Cl]+ (en = 1,2-diaminoethane)
(Peacock and Sadler, 2008) and [RuII(arene)(HOPO)Cl] com-
plexes (HOPO = hydroxypyr(id)one) (Kandioller et al., 2011).
The arene ligand plays a major role in the anticancer activity
of ethylene-1,2-diamine compounds and related drug candidates
(Habtemariam et al., 2006; Hanif et al., 2010b), while in other
cases it has less impact on cytotoxicity (Mendoza-Ferri et al.,
2009), unless modified with bioactive groups (Hartinger et al.,
2012). Furthermore, the arene ligand imparts hydrophobic char-
acter to the molecule, which facilitates the passive diffusion
through the cell membrane, enhancing the cellular accumulation.
Some arene ligands facilitate the interaction of Ru(arene) com-
plexes with nucleobases (Chen et al., 2003) and proteins (Casini
et al., 2008). However, in general the co-ligands at the metal
center determine the anticancer activity of this compound class.
For example, the combination of ligands en/Cl yields a complex
with activity in a xenograft model (Aird et al., 2002) while pta
derivatives reduce the number and weight of metastases (Dyson,
2007).
In recent years, we have reported the development of
phosphorus-substituted sugar derivatives with the aim to exploit
the enhanced glucose uptake in tumors due to increased gly-
colytic activity in cancer cells (Berger et al., 2008; Hanif et al.,
2010a, 2011, 2012a,b; Nazarov et al., 2012). These organometal-
lic compounds exhibit selective cytotoxicity in tumorigenic cell
lines, and dichlorido(η6-p-cymene)(3,5,6-bicyclophosphite-1,2-
O-cyclohexylidene-α-D-glucofuranoside)ruthenium(II) 1b was
found to be more cytotoxic than RAPTA-C in in vitro assays
(Berger et al., 2008). The carbohydrate compounds are prone to
hydrolysis, and they undergo aquation of the first halido ligand
in aqueous solution, followed by hydrolysis of a P–O bond of
the phosphite ligand, and finally formation of dinuclear species
(Berger et al., 2008). The aquation can be hindered or suppressed
by replacing ruthenium with osmium and chlorido ligands with
dicarboxylates (Hanif et al., 2010a, 2011).
Functionalizing metal-arene compounds with modified sug-
ars should yield hybrid molecules with altered pharmacological
properties, such as improved biocompatibility, bioavailability,
activity and targeting potential (Gottschaldt and Schubert, 2009).
Furthermore, the biophysical characteristics of compounds are
significantly modified by attaching carbohydrate moieties to
metal-arene units (Hartinger et al., 2008). In order to study the
effect of the arene ligand on anticancer potency, a series of new
RuII(arene) complexes bearing carbohydrate-derived phosphite
ligands was prepared and compared to structurally related RAPTA
derivatives, also with regard to their cathepsin B inhibitory
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FIGURE 1 | Structures of selected RuII(arene) anticancer complexes.
activity, which is a potential target for anticancer metallodrugs
(Fricker, 2010).
MATERIALS AND METHODS
MATERIALS
All chemicals were obtained from commercial suppliers
and used as received and were of analytical grade except
for methanol and CH2Cl2 that were dried using standard
procedures. The complexes bis[dichlorido(η6-biphenyl)
ruthenium(II)] (Mendoza-Ferri et al., 2009), bis[dichlorido
(η6-p-cymene)ruthenium(II)], bis[dichlorido(η6-benzene)
ruthenium(II)], bis[dichlorido(η6-toluene)ruthenium(II)]
(Bennett and Smith, 1974; Bennett et al., 1982), dichlorido(η6-
p-cymene)(3,5,6-bicyclophosphite-1,2-O-isopropylidene-α-D-
glucofuranose)ruthenium(II) 1a, dichlorido(η6-p-cymene)(3,5,
6-bicyclophosphite-1,2-O-cyclohexylidene-α-D-glucofuranose)
ruthenium(II) 1 b (Berger et al., 2008), and the ligands 3,5,6-
bicyclophosphite-1,2-O-isopropylidene-α-D-glucofuranoside I
and 3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-α-D-gluco-
furanoside II (Kochetkov et al., 1976) were synthesized using
literature procedures. All reactions were carried out in dry
solvents under an inert atmosphere. 1 H, 13C{1H} and 31P{1H}
NMR spectra were recorded at 25◦C on a Bruker FT NMR spec-
trometer Avance III 500MHz at 500.10 (1H), 125.75 (13C{1H})
and 202.44MHz (31P{1H}) or a Bruker Avance 400 FT NMR
spectrometer at 400.13 (1H), 100.63 (13C{1H}) and 161.98MHz
(31P{1H}). 2D NMR spectra were collected in a gradient-
enhanced mode. Melting points were measured on a Büchi
B-540 apparatus and are uncorrected. Elemental analysis was
performed by the Laboratory for Elemental Analysis, Faculty of
Chemistry, University of Vienna, on a Perkin–Elmer 2400CHN
Elemental Analyzer and at the Microanalytical Laboratory of
the EPFL. Electrospray ionization mass spectra were recorded
on a Bruker esquire3000. Na2EDTA·(p.a., Fisher Scientific),
NaOH (Fluka), tris(hydroxymethyl)aminoethane, glacial acetic
acid (p.a., Acros), and MilliQ H2O (18.2M, Synergy 185UV
Ultrapure, Millipore, France) were used for the preparation of
TAE buffer for gel electrophoresis studies. Loading buffer (6×),
pBR322 DNA (0.5μg/μL) and GeneRuler™ 1 kb DNA ladder
(0.5μg/μL) were obtained from Fermentas.
General procedure for the synthesis of 2–6
A mixture of bis[dichlorido(η6-arene)ruthenium(II)] (1 eq.) and
the phosphite ligand (2 eq.) in dry CH2Cl2 (30ml) was stirred
for 3 h at 40◦C. The solvent was reduced to about 3mL on a
rotary evaporator, and diethyl ether (20mL) was added resulting
in orange or brown precipitates which were filtered, washed with
diethyl ether (2 × 5mL), and dried under vacuum.
Dichlorido(η6-benzene)(3,5,6-bicyclophosphite-1,2-O-
cyclohexylidene- α-D-glucofuranose)ruthenium(II) 2
The title compound was synthesized from 3,5,6-bicyclo-
phosphite-1,2-O-cyclohexylidene-α-D-glucofuranose (58mg,
0.2mmol) and [(η6-benzene)RuCl(μ-Cl)]2 (50mg, 0.1mmol)
following the general procedure.
Yield: 104mg (96%); m.p. 295–297◦C (decomp); elemental
analysis calcd. for C18H23Cl2O6PRu·0.5CH2Cl2: C 38.25, H 4.16;
found: C 38.21, H 4.19%; MS (ESI+): m/z: 560.7 [M + Na]+;
1H NMR (500.10MHz, CDCl3, 25◦C): δ = 6.20 (brs, 1H; H-
1), 5.89 (s, 6H; H-Ar), 5.10–5.13 (m, 1H; H-5), 4.83 (brs, 1H;
H-3), 4.75 (brs, 1H; H-2), 4.48-4.50 (m, 1 H; H-6), 4.31–4.33
(m, 2 H; H-6′, H-4), 1.57–1.70 (m, 10 H; C6H10) ppm. 13C{1H}
NMR (125.75MHz, CDCl3, 25◦C): δ = 113.3 (Ccyc), 105.4 (C-1),
91.2 (C-Ar), 83.4 (C-2), 79.5 (C-3), 75.7 (C-4), 75.2 (C-5), 71.5
(C-6), 36.5 (C6H10), 35.8 (C6H10), 24.8 (C6H10), 23.9 (C6H10),
23.5 (C6H10) ppm. 31P{1H}NMR (202.44MHz, CDCl3, 25◦C):
δ = 132.7 ppm.
Dichlorido(η6-toluene)(3,5,6-bicyclophosphite-1,2-O-
isopropylidene- α-D-glucofuranose)ruthenium(II) 3
The title compound was synthesized from 3,5,6-bicyclo-
phosphite-1,2-O-isopropylidene-α-D-glucofuranose (99mg,
0.4mmol) and [(η6-toluene)RuCl(μ-Cl)]2 (106mg, 0.2mmol)
following the general procedure.
Yield: 201mg (97%); m.p. 180–181◦C (decomp); elemen-
tal analysis calcd. for C16H21Cl2O6PRu·0.25CH2Cl2: C 36.58,
H 4.06; found: C 36.93, H 4.22%; MS (ESI+): m/z: 534.6
[M + Na]+; 1H NMR (500.10MHz, CDCl3, 25◦C): δ = 6.19
[d, 3J(H,H) = 3Hz, 1 H; H-1], 5.80–5.82 (m, 2 H; H-Ar), 5.58
(brs, 2 H; H-Ar), 5.52 (brs, 1 H; H-Ar), 5.09–5.12 (m, 1 H;
H-5), 4.81 (brs, 1H; H-3), 4.74 [d, 3J(H,H) = 2Hz, 1 H; H-
2], 4.44–4.48 (m, 1 H; H-6), 4.31–4.33 (m, 2 H; H-6′, H-4),
2.34 (s, 3 H; Ar-CH3), 1.52 [s, 3 H; C(CH3)2], 1.36 [s, 3 H;
C(CH3)2] ppm. 13C{1H}NMR (125.75MHz, CDCl3, 25◦C): δ =
113.0 [C(CH3)2], 112.6 (C-Ar), 105.7 (C-1), 91.0 (C-Ar), 90.6
(C-Ar), 83.7 [3J(C,P) = 6Hz, C-2], 82.2 (C-Ar), 81.8 (C-Ar),
79.2 [3J(C,P) = 8Hz, C-3], 77.2 (C-Ar), 76.8 [3J(C,P) = 6Hz, C-
4], 74.8 [3J(C,P) = 5Hz, C-5], 69.9 [3J(C,P) = 8Hz, C-6], 26.9
[C(CH3)2], 26.3 [C(CH3)2], 19.2 (Ar-CH3) ppm. 31P{1H}NMR
(202.44MHz, CDCl3, 25◦C): δ = 134.5 ppm.
Dichlorido(η6-toluene)(3,5,6-bicyclophosphite-1,2-O-
cyclohexylidene- α-D-glucofuranose)ruthenium(II) 4
The title compound was synthesized from 3,5,6-bicyclophos-
phite-1,2-O-cyclohexylidene-α-D-glucofuranose (58mg,
0.2mmol) and [(η6-toluene)RuCl(μ-Cl)]2 (53mg, 0.1mmol)
following the general procedure.
Yield: 107mg (95%); m.p. 281–283◦C (decomp); elemen-
tal analysis calcd. for C19H25Cl2O6PRu·0.15CH2Cl2: C 39.37,
H 4.40; found: C 39.06, H 4.40%; MS (ESI+): m/z: 574.6
[M + Na]+; 1H NMR (500.10MHz, CDCl3, 25◦C): δ = 6.18 [d,
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3J(H,H) = 4Hz, 1 H; H-1], 5.80–5.82 (m, 2H; H-Ar), 5.58 (brs,
2H; H-Ar), 5.48–5.51 (m, 1H; H-Ar), 5.08–5.12 (m, 1H; H-5),
4.82 (brs, 1H; H-3), 4.73 (brs, 1H; H-2), 4.44–4.48 (m, 1H; H-6),
4.32–4.34 (m, 2H; H-6′, H-4), 2.34 (s, 3H; Ar-CH3), 1.67–1.70
(m, 4H; C6H10), 1.56–1.58 (m, 6H; C6H10) ppm. 13C{1H}NMR
(125.75MHz, CDCl3, 25◦C): δ = 113.7 (Ccyc), 112.7 (C-Ar),
105.3 (C-1), 91.1 (C-Ar), 90.7 (C-Ar), 83.4 [3J(C,P)= 7Hz, C-2],
82.3 (C-Ar), 81.6 (C-Ar), 79.4 [3J(C,P) = 8Hz, C-3], 77.4 (C-
Ar), 76.6 [3J(C,P) = 6Hz, C-4], 74.9 [3J(C,P) = 5Hz, C-5], 69.8
[3J(C,P)= 8Hz, C-6], 36.9 (C6H10), 36.2 (C6H10), 24.8 (C6H10),
24.2 (C6H10), 23.5 (C6H10), 19.2 (CH3) ppm. 31P{1H}NMR
(202.44MHz, CDCl3, 25◦C): δ = 134.4 ppm.
Dichlorido(η6-biphenyl)(3,5,6-bicyclophosphite-1,2-O-
isopropylidene- α-D-glucofuranose)ruthenium(II) 5
The title compound was synthesized from 3,5,6-bicyclo-
phosphite-1,2-O-isopropylidene-α-D-glucofuranose (99mg,
0.4mmol) and [(η6-biphenyl)RuCl(μ-Cl)]2 (131mg, 0.2mmol)
following the general procedure.
Yield: 217mg (91%); m.p. 178–179◦C (decomp); elemental
analysis calcd. for C21H23Cl2O6PRu·0.25CH2Cl2: C 42.85, H
3.98; found: C 42.97, H 3.88%; MS (ESI+): m/z: 596.6 [M +
Na]+; 1HNMR (500.10MHz, CDCl3, 25◦C): δ = 7.69–7.71 (m,
2H; H-Ar), 7.48–7.50 (m, 3H; H-Ar), 6.18–6.22 (m, 3H; H-
Ar), 5.99 [d, 3J(H,H) = 4Hz, 1H; H-1], 5.88 (brs, 2H; H-Ar),
5.03–5.07 (m, 1H; H-5), 4.72 (brs, 1H; H-3), 4.38–4.44 (m,
2H; H-6′, H-2), 4.26 (brs, 1H; H-4), 4.19 (brs, 1H; H-6), 1.50
[s, 3H; C(CH3)2], 1.33 [s, 3H; C(CH3)2] ppm. 13C{1H}NMR
(125.75MHz, CDCl3, 25◦C): δ = 133.7 (C-Ar), 130.1 (C-Ar),
129.0 (C-Ar), 128.8 (C-Ar), 128.7 (C-Ar), 127.3 (C-Ar), 112.5
[C(CH3)2], 108.3 (C-Ar), 105.7 (C-1), 91.2 (C-Ar), 90.8 (C-Ar),
89.9 (C-Ar), 88.9 (C-Ar), 88.2 (C-Ar), 83.5 [3J(C,P) = 5Hz,
C-2], 79.1 [3J(C,P) = 8Hz, C-3], 76.8 (C-4), 74.9 [3J(C,P) =
5Hz, C-5], 69.6 (C-6), 26.9 [C(CH3)2], 26.3 [C(CH3)2] ppm.
31P{1H}NMR (202.44MHz, CDCl3, 25◦C): δ = 132.3 ppm.
Dichlorido(η6-biphenyl)(3,5,6-bicyclophosphite-1,2-O-
cyclohexylidene- α-D-glucofuranose)ruthenium(II) 6
The title compound was synthesized from 3,5,6-bicyclo-
phosphite-1,2-O-cyclohexylidene-α-D-glucofuranose (58mg,
0.2mmol) and [(η6-biphenyl)RuCl(μ-Cl)]2 (65mg, 0.1mmol)
following the general procedure.
Yield: 119mg (93%); m.p. 170–172◦C (decomp); elemental
analysis calcd. for C24H27Cl2O6PRu·0.3CH2Cl2: C 45.61, H 4.35;
found: C 45.27, H 4.38%; MS (ESI+): m/z: 636.7 [M + Na]+;
1H NMR (500.10MHz, CDCl3, 25◦C): δ = 7.62–7.69 (m, 2H;
H-Ar), 7.46–7.49 (m, 3H; H-Ar), 6.17–6.20 (m, 3H; H-Ar), 5.98
[d, 3J(H,H) = 4Hz, 1H; H-1], 5.87 (brs, 2H; H-Ar), 5.03–5.05
(m, 1H; H-5), 4.73 (brs, 1H; H-3), 4.43–4.46 (m, 2H; H-6′,
H-2), 4.26 (brs, 1H; H-4), 4.18 (brs, 1H; H-6), 1.65–1.67 (m,
4H; C6H10), 1.54–1.58 (m, 6H; C6H10) ppm. 13C{1H} NMR
(125.75MHz, CDCl3, 25◦C): δ = 133.6 (C-Ar), 130.1 (C-Ar),
129.0 (C-Ar), 128.8 (C-Ar), 128.6 (C-Ar), 127.2 (C-Ar), 113.2
(Ccyc), 108.5 (C-Ar), 105.4 (C-1), 91.3 (C-Ar), 90.6 (C-Ar), 90.0
(C-Ar), 89.0 (C-Ar), 88.3 (C-Ar), 83.2 [3J(C,P) = 6Hz, C-2],
79.3 [3J(C,P) = 8Hz, C-3], 76.6 (C-4), 75.0 [3J(C,P) = 5Hz, C-
5], 70.0 (C-6), 36.5 (C6H10), 35.8 (C6H10), 24.8 (C6H10), 23.9
(C6H10), 23.5 (C6H10) ppm. 31P{1H}NMR (202.44MHz, CDCl3,
25◦C): δ = 132.4 ppm.
Dichlorido(η6-phenoxyethanol)(3,5,6-bicyclophosphite-1,2-O-
isopropylidene-α-D-glucofuranoside)ruthenium(II) 7
3,5,6-Bicyclophosphite-1,2-O-isopropylidene-α-D-glucofurano-
side (200mg, 0.8mmol) was added to a solution of {(η6-phenoxy-
ethanol)RuCl(μ-Cl)}2 (250mg, 0.4mmol) in CH2Cl2 (30mL).
The reaction mixture was stirred for 12 h at room temperature.
The insoluble residue was removed by filtration and diethyl
ether was added to a red solution in order to precipitate the
crude product. The pure product was obtained by purification
on a silica gel column with CH2Cl2: MeOH (20: 1) as eluent.
Yield: 268mg (60%); m.p. 120–121◦C (decomp); elemental
analysis calcd. for C17H23O8RuPCl2: C 36.57, H 4.15; Found:
C 36.96, H 4.35%; MS (ESI+) m/z: 522 [M - Cl]+; 1H NMR
(400.13MHz, D2O, 25◦C): δ = 6.25 [d, 3J(H,H) = 3.5Hz, 1H;
H-1], 6.20 (m, 2H; H-Ar), 5.65 (m, 2H; H-Ar), 5.30 (m, 1H;
H-Ar), 5.24 (m, 1H; H-5), 4.98 (m, 1H; H-3), 4.89 [d, 3J(H,H)
= 3.5Hz, 1H; H-2], 4.86 [dd, 2J(H,H) = 11.8Hz, 3J(H,P) =
9.9Hz, 1H; H-6], 4.57 (m, 1H; H-4), 4.32 (m, 1H; H-6′), 4.3
[t, 3J(H,H) = 4.3Hz, 2H; O-CH2-CH2-OH], 3.94 [t, 3J(H,H)
= 4.3Hz, 2H; O-CH2-CH2-OH], 1.51 (s, 3H; CH3), 1.37 (s,
3H; CH3) ppm.13C{1H}NMR (100.63MHz, CDCl3, 25◦C):
δ = 145.3 (C-Ar), 112.6 [C(CH3)2], 105.8 (C-1), 94.3 (C-Ar),
93.7 (C-Ar), 83.6 [3J(C,P) = 6.1Hz; C-2], 79.0 [2J(C,P) =
8.0Hz; C-3], 77.2 (C-4), 74.7 (C-Ar or C-5), 73.8 (C-Ar or C-5),
72.8 (C-Ar, O-CH2), 69.0 (C-6), 60.8 (CH2-OH), 26.9 (CH3),
26.2 (CH3) ppm.31P{1H}NMR (161.98MHz, CDCl3, 25◦C):
δ = 137.1 ppm.
Dichlorido(η6-phenoxyethanol)(3,5,6-bicyclophosphite-1,2-O-
cyclohexylidene-α-D-glucofuranoside)ruthenium(II) 8
3,5,6-Bicyclophosphite-1,2-O-cyclohexylidene-α-D-glucofurano-
side (230mg, 0.8mmol) was added to a solution of {(η6-phenoxy-
ethanol)RuCl(μ-Cl)}2 (250mg, 0.4mmol) in CH2Cl2 (30mL).
The reaction mixture was stirred for 12 h at room temperature.
The insoluble residue was removed by filtration and diethyl ether
was added to a red solution in order to precipitate the crude
product. The pure product was obtained by purification on a
silica gel column with CH2Cl2: MeOH (20: 1) as eluent. Yield:
350mg (73%); m.p. 90–91◦C (decomp); elemental analysis calcd.
for C20H27O8RuPCl2: C 40.14, H 4.55; Found: C 40.41, H 4.73%;
MS (ESI+) m/z: 563 [M - Cl]+; 1H NMR (400.13MHz, CD2Cl2,
25◦C): δ = 6.19 [d, 3J(H,H) = 4Hz, 1H; H-1], 5.98 (m, 2H; H-
Ar), 5.53 (m, 2H; H-Ar), 5.13 (m, 1H; H-Ar), 5.10 (m, 1H; H-5),
4.82 (m, 1H; H-3), 4.73 [d, 3J(H,H) = 4Hz, 1H; H-2], 4.50 [dd,
2J(H,H) = 12Hz, 3J(H,P) = 9Hz, 1H; H-6], 4.40 [t, 3J(H,H) =
4Hz, 2H; O-CH2-CH2-OH], 4.33 (m, 1H; H-4), 4.28 (m, 1H;
H-6′), 3.97 [t, 3J(H,H) = 4Hz, 2H; O-CH2-CH2-OH], 3.37
(brs, 1H;OH), 1.70–1.24 (m, 10H; CH2) ppm. 13C{1H}NMR
(100.63MHz, CD2Cl2, 25◦C): δ = 145.0 (C-Ar), 113.2 (C6H10),
105.4 (C-1), 94.0 (C-Ar), 93.6 (C-Ar), 83.3 [3J(C,P) = 6.0Hz;
C-2], 79.2 [2J(C,P) = 8.3Hz; C-3], 76.8 [3J(C,P) = 4.9Hz;
C-4], 74.6 [2J(C,P) = 5.7Hz; C-5], 73.7 (C-Ar), 72.9 (C-Ar),
72.7 (O-CH2), 69.2 [2J(C,P) = 9.2Hz; C-6], 60.6 (CH2-OH),
36.4 (C6H10), 35.7 (C6H10), 24.8 (C6H10), 23.9 (C6H10), 23.6
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(C6H10) ppm. 31P{1H} NMR (161.98MHz, CD2Cl2, 25◦C): δ =
137.1 ppm.
Hydrolysis and reactivity with 9-ethylguanine (9-EtG)
For hydrolysis studies, the compounds were dissolved in D2O and
the samples were analyzed by 1H and 31P{1H} NMR spectroscopy
after 1, 24, 48 and 96 h. For 9-ethylguanine binding experiments,
the complexes were mixed at molar ratios of 1: 1 and 1: 2 (com-
plex: 9-EtG) in D2O and reaction progress was monitored by
1H and 31P{1H} NMR spectroscopy after 1, 24 and 96 h, while
samples were kept at room temperature during this time period.
DNA interaction studies
The structural modification of DNA by 2, 4, and 6 was tested by
agarose gel electrophoresis with the plasmid pBR322. TAE (1x)
buffer was employed as incubation medium. Stock solutions of
1mM of complex 2, 4, and 6 were prepared in TAE (1x) buffer,
diluted with TAE (1x) buffer and stored at −20 ◦C. The plasmid
pBR322 was diluted with TAE (1x) buffer as well. Incubationmix-
tures were prepared to yield rb-values corresponding to 0.01, 0.05,
0.10, 0.50, 1.00 and 5.00.
The agarose gels consisted of 1% agarose in TAE (1×) buffer,
and the incubation mixtures were subject to 35min running time
at 100V and 70mA in a PerfectBlue™ Mini S (PEQLAB) GE
chamber. The DNA bands were stained with ethidium bromide
(1μl/mL) and were processed and analyzed with the gel docu-
mentation system GenoView UV-source and GenoSoft Version
3.08 C (VWR).
Cathepsin B inhibition assay
Crude bovine spleen cathepsin B (cat B) was purchased from
Sigma (C6286) and used without further purification. The colori-
metric cat B assay was performed in 100mM sodium phosphate,
1mM EDTA, 0.025% polyoxyethylene (23) lauryl ether (BRIJ),
pH 6.0, using Na-CBZ-L-lysine p-nitrophenyl ester (CBZ = N-
carbobenzoxy) as substrate. For the enzyme to be catalytically
functional, the active site cysteine needs to be in a reduced
form which was accomplished before dilution with an excess of
dithiothreitol (DTT) for 1 h at 30◦C. IC50 determinations were
performed in triplicate using a fixed enzyme concentration of
500 nM and a fixed substrate concentration of 200μM. Inhibitor
concentrations ranged from 0.3 to 200μM.
The enzyme and inhibitor were co-incubated at 30◦C over a
period of 24 h prior to the addition of substrate. Activity was
measured over 3min at 326 nm. Colorimetric readings were per-
formed on a Lambda 20 Bio spectrophotometer (Perkin-Elmer).
Cytotoxicity studies
Cell lines and culture conditions. CH1 cells originate from an
ascites sample of a patient with a papillary cystadenocarcinoma
of the ovary and were a gift from Lloyd R. Kelland, CRC Centre
for Cancer Therapeutics, Institute of Cancer Research, Sutton,
UK. SW480 (adenocarcinoma of the colon, human), and A549
(non-small cell lung cancer, human) cells were provided by
Brigitte Marian (Institute of Cancer Research, Department of
Medicine I, Medical University of Vienna, Austria). All cell culture
media and reagents were obtained from Sigma-Aldrich Austria.
Cells were grown in 75 cm2 culture flasks (Iwaki) as adherent
monolayer cultures in Eagle’s Minimal Essential Medium (MEM)
supplemented with 10% heat-inactivated fetal calf serum, 1% v/v
non-essential amino acids (from 100× ready-to-use stock), 1mm
sodium pyruvate and 4mm L-glutamine (complete medium).
Cultures were maintained at 37◦C in a humidified atmosphere
containing 95% air and 5% CO2.
MTT assay conditions. Cytotoxicity was determined using the
colorimetric MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide, Fluka) assay. CH1, SW480 and A549
cells were harvested from the culture flasks by trypsinization,
and 100μL aliquots were seeded into 96-well microculture plates
(Iwaki/Asahi Technoglass, Gyouda, Japan) in complete medium.
Densities of 1.5 × 103 (CH1), 2.5 × 103 (SW480) and 4 × 103
(A549) cells per well were chosen in order to ensure exponential
growth of untreated controls throughout the experiment. Cells
were allowed to settle for 24 h. Then, the test compounds were
dissolved and serially diluted in complete medium, and 100μL
aliquots were added to the microcultures. Cells were exposed
to the test compounds for 96 h. After exposure, all media were
replaced with 1:6 MTT/RPMI mixture (100μL per well) con-
taining MTT solution in phosphate-buffered saline (5mg/ml)
and MTT/RPMI1640 culture medium (supplemented with 10%
heat-inactivated fetal calf serum and 4mM L-glutamine). After
incubation for 4 h, the supernatants were removed, and the for-
mazan crystals formed in viable cells were dissolved in 150μL
DMSO per well. Optical densities were measured at 550 nm with
a microplate reader (Tecan Spectra Classic), using a reference
wavelength of 690 nm to correct the unspecific absorption. The
quantity of viable cells was expressed in terms of T/C values by
comparison to untreated control, and 50% inhibitory concentra-
tions (IC50) were calculated from concentration-effect curves by
interpolation. Evaluation is based on means from at least three
independent experiments, each comprising three replicates per
concentration level.
Determination of cellular accumulation of the complexes
The cellular accumulation study was conducted following a pre-
viously published protocol (Egger et al., 2009). SW480 cells were
seeded in 6-well plates (Iwaki/Asahi Technoglass, Gyouda, Japan)
in 2.5mL complete medium (MEM) per well in densities of about
3 × 105 cells per well. Cell microcultures were incubated in a
moist atmosphere at 37◦C for 24 h prior to exposure to the test
compounds. The cell number was determined using trypan blue
staining in parallel microcultures during the 2 h exposure period.
After exposure the medium was removed, cells were washed
with PBS and consecutively lyzed with 0.5mL sub-boiled HNO3
(conc.) per well for 1 h. The Ru concentration was quantified
by ICP-MS in presence of 0.5μM indium used as internal stan-
dard. Results are based on three independent experiments, each
consisting of three replicates.
RESULTS AND DISCUSSION
In order to further improve the specificity and efficacy of sugar-
based RAPTA analogues, we have prepared further compounds
carrying benzene, toluene, biphenyl and phenoxyethanol as the
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π-bound arene ligands, in order to explore the influence of the
arene ligand on the antitumor activity of the compounds as well
as on their modes of action. The organometallic RuII-chlorido
complexes 2–8 were synthesized by reacting 3,5,6-bicyclo-
phosphite-1,2-O-isopropylidene-α-D-glucofuranoside I or 3,5,6-
bicyclophosphite-1,2-O-cyclohexylidene-α-D-glucofuranoside II
with the respective bis[dichlorido(η6-arene)ruthenium(II)] pre-
cursor in CH2Cl2 (Figure 2) (Berger et al., 2008; Hanif et al.,
2010a). All the complexes were obtained in very good yield and
were characterized by 1D and 2D NMR spectroscopy, ESI-MS,
and elemental analysis. In the 1H NMR spectra, protons of the
coordinated arene ligands give rise to signals that appear in the
range 5–6 ppm. Complexes 5 and 6, which contain a η6-biphenyl
ligand, exhibit additional resonances due to the aromatic protons
from the second phenyl ring at ca. 7–8 ppm. The benzene ligand
in 2 gives a singlet resonance at 6.20 ppm. The coordination of
the P-donor sugar-based ligands to the metal center results in a
dramatic change in the 31P{1H} NMR singlet resonance from ca.
117 to 135 ppm, which is similar to that of analogous compounds
(Berger et al., 2008). Moreover, the presence of the NMR active
phosphorus nucleus induces splitting of some of the carbon sig-
nals of coordinated arene moieties due to P-C coupling (Berger
et al., 2008). ESI-MS further confirms the structures with peaks
of high relative intensity that may be assigned to [M+Na]+ or
[M–Cl]+ ions for all compounds.
The hydrolysis of 2, 3, 7, and 8 was studied by 31P{1H} NMR
spectroscopy and parallels earlier findings for 1a (Berger et al.,
2008). Dissolution of 2 and 3 in water results after 1 h-incubation
in a single peak at about 136 ppm, which is assignable to the par-
ent compound and indicates stability within this time period.
Within 24 h, two additional peaks of equal relative intensity at
137.4 and 136.8 ppm appear due to formation of diastereomers
by exchange of a single chlorido ligand with an aqua molecule.
This was accompanied by the cleavage of a P–O bond as indi-
cated by signals of equal relative intensity at 95.7 and 94.5 ppm,
while an additional signal at 94.7 ppm is assigned to a compound
in which P–O bond cleavage occurred. The 31P{1H} NMR spec-
trum recorded after 48 h contains two additional signals at 123.8
FIGURE 2 | Synthesis of the dichlorido–RuII compounds (2–8) with
P-derived sugar ligands (I, II).
and 122.4 ppm, probably due to formation of dimeric species.
The sequence of formation of hydrolytic species is similar to that
observed for related ruthenium(II) compounds (Scolaro et al.,
2005; Berger et al., 2008; Scolaro et al., 2008; Hanif et al., 2010a;
Nazarov et al., 2012). Extending the reaction time to 96 h did not
result in the formation of additional species, and it seems that
an equilibrium has been reached with 60–70% of the compound
remaining in its original form. A similar process was observed for
7 and 8, demonstrating that the addition of a hydroxyl function-
ality to the arene ligand does not alter the aquation profile.
BIOLOGICAL EVALUATION
The cancer-inhibiting potential of 2–6 and 8 was determined in
human SW480 colon adenocarcinoma, CH1 ovarian cancer and
A549 non-small cell lung cancer cells by using the MTT assay.
The obtained results are compared to those of analogous Ru(II)
compounds in Table 1, and the concentration–effect curves of
1b, 2, 4, 6, and 8 in CH1 cells, which are usually most sensitive
to the treatment with metal compounds, are shown in Figure 3.
Table 1 | Cellular accumulation in SW480 colon cancer cells and
in vitro anticancer activity (mean IC50 values ± standard deviations)
of 1–6 and 8 in human ovarian cancer (CH1), colon adenocarcinoma
(SW480), and non-small cell lung cancer (A549) cells (exposure time
96h).
Compound Cellular uptake/
Ru [fg/cell]
IC50 values/μM
CH1 SW480 A549
1a 10 ± 2 60 ± 14a 361 ± 122a 498 ± 17a
1b 20 ± 2 29 ± 4a 150 ± 19a 223 ± 14a
2 29 ± 6 118 ± 36 129 ± 13 417 ± 68
3 n.d. 164 ± 47 276 ± 6 427 ± 163
4 18 ± 3 92 ± 22 99 ± 13 486 ± 55
5 74 ± 9 29 ± 3 26 ± 5 >160
6 224 ± 33 3.9 ± 0.3 5.3 ± 0.9 56 ± 9
8 4 ± 1 189 ± 3 260 ± 52 314 ± 32
RAPTA-C n.d. 65 ± 15 171 ± 59 >515
aFrom Berger et al. (2008); n.d., not determined.
FIGURE 3 | Concentration–effect curves of 1b, 2, 4, 6, and 8 in CH1 cells.
www.frontiersin.org October 2013 | Volume 1 | Article 27 | 5
Hanif et al. Carbohydrate-based anticancer ruthenium(II)–arene complexes
Variation in the arene ligand of the Ru complexes has a strong
influence on antiproliferative activity, which is improved with
increasing the lipophilic character of the arene and carbohydrate
ligands in line with the cellular accumulation of the compounds
(Table 1).
Carbohydrate compounds potentially accumulate in tumors
due to their high demand for glucose as a result of their
upregulated glycolytic energy production. Recently, fluorescent
Ru(arene) complexes bearing the pta or a sugar phosphite ligand
were shown to accumulate in cells to a similar extent (Nazarov
et al., 2012). In the present study, the most lipophilic compound
6, according to aqueous solubility, with the biphenyl ligand and
a cyclohexylidene moiety at the sugar-derived ligand was most
efficiently taken up into the cell and was also the most active
derivative with IC50 values in the low micromolar range. The
following order of cytotoxicity was observed with regard to varia-
tion of the arene ligand in 1b, 2, 4 and 6 with the identical sugar
moiety: biphenyl > cymene > toluene > benzene.
Complex 3 was chosen for DNA interaction studies with 9-
ethylguanine (9-EtG), and the reaction was monitored by NMR
spectroscopy. Complex 3 appears to form adducts with the
DNA model nucleobase 9-EtG via N7 of the guanine moiety as
shown by 1H NMR spectroscopy where a low-field shift from
7.85 to 8.29 ppm was observed for H8 of guanine. Analysis by
31P{1H} NMR spectroscopy immediately after mixing 3 with
9-EtG revealed a single peak at 135.9 ppm for the unreacted
compound. Within 1 h, two additional signals at 136.6 and
137.2 ppm appear due to the formation of diastereomers by
exchange of one of the chlorido ligands with 9-EtG. However,
after 24 h several species were formed, including signals at
93.3 and 95.1 ppm indicative of cleavage of a P-O bond, sim-
ilar to the behavior observed for related analogous complexes
(Berger et al., 2008).
Furthermore, the reactivity to DNA and impact on its sec-
ondary structure was studied by determining the electrophoretic
mobility of a dsDNA plasmid in cell-free experiments. However,
no influence of complexes 2, 4, or 6 on the electrophoretic
mobility of pBR322 plasmid DNA was observed at rb-values
(metal-to-nucleobase ratio) up to 5 within the incubation period
of 2 h. Consequently, the incubation period was increased to 4
and 6 h for complexes 4 and 6, which did not lead to any observ-
able change either, making it unlikely that the cytotoxic effect is
related to DNA binding interactions.
For this reason the compounds were evaluated as inhibitors
of cat B since bifunctional ruthenium(arene) compounds have
been shown to be good inhibitors (Casini et al., 2008). Cathepsin
B has been proposed to participate in metastasis, angiogen-
esis, and tumor progression, and therefore it is believed to
be an important target for the control of tumor progres-
sion (Mohamed and Sloane, 2006). Cat B inhibitors reduce
both tumor cell motility and invasiveness in vitro (Frlan and
Gobec, 2006), and many palladium, rhenium, gold and ruthe-
nium complexes, such as members of the RAPTA family and
particularly RAPTA-C and RAPTA-T (Casini et al., 2008),
inhibit cat B potently (Casini et al., 2008; Mura et al., 2010).
Indeed, the sugar-derived phosphite based ruthenium com-
plexes 1a, 1b, and 6 exhibit IC50 values in the low micromolar
Table 2 | IC50 (μM) of 1a, 1b, RAPTA-C, and RAPTA-T against bovine
cat B.
Compound IC50 values/μMCat B
1a 1.5 ± 0.2
1b 4.0 ± 0.6
6 8.0 ± 0.4
RAPTA-C 2.5 ± 0.5 a
RAPTA-T 1.5 ± 0.2 a
aFrom Casini et al. (2008).
range (Table 2) and thus inhibit cat B to an extent similar to
RAPTA-T. However, no correlation with cytotoxicity data was
observed.
CONCLUDING REMARKS
In this paper, we report on the synthesis and biological eval-
uation of RuII(η6-arene) complexes with carbohydrate-derived
phosphorus-containing ligands. The cytotoxicity appears to be
dependent on the lipophilicity, i.e., themost lipophilic compound
is the most cytotoxic. Moreover, such complexes are known to
exhibit certain selectivity for tumor cells over non-tumorigenic
cells and are also active in cisplatin-resistant cancer cells (Berger
et al., 2008; Hanif et al., 2010a). The arene ligand has little influ-
ence on the hydrolysis behavior. Binding to 9-EtG as assayed by
NMR spectroscopy suggests that some covalent interaction with
DNA is possible, but no effect on the electrophoretic mobil-
ity and therewith the secondary structure of plasmid DNA was
observed. Studies on the inhibition of cathepsin B revealed that
the carbohydrate compounds are potent inhibitors compara-
ble to the metastasis inhibitors RAPTA-C and RAPTA-T, which
appear to interact with histone proteins of the nucleosome core
particle (Wu et al., 2011). However, further experiments are
required to draw unambiguous conclusions on themode of action
of these compounds. Overall, carbohydrate-based metal(arene)
complexes have demonstrated promising antiproliferative activ-
ity in in vitro assays, but only in vivo experiments will give deeper
insight into the potential of these compounds as anticancer
drugs.
ACKNOWLEDGMENTS
We thank the Higher Education Commission of Pakistan
(Muhammad Hanif), the Austrian Exchange Service (ÖAD),
the Hochschuljubiläumsstiftung Vienna, the FFG – Austrian
Research Promotion Agency (811591), the Austrian Council
for Research and Technology Development (IS526001), COST
D39 and CM1105 and the Austrian Science Fund for finan-
cial support. This research was supported by a Marie Curie
Intra European Fellowship within the 7th European Community
Framework Programme project 220890-SuRuCo and Russian
Foundation for Basic Research 13-03-00513 and 13-03-12460
(Alexey A. Nazarov). We gratefully acknowledge Michaela
Hejl for performing some of the in vitro anticancer assays
and Prof. Markus Galanski for recording the 2D NMR
spectra.
Frontiers in Chemistry | Inorganic Chemistry October 2013 | Volume 1 | Article 27 | 6
Hanif et al. Carbohydrate-based anticancer ruthenium(II)–arene complexes
REFERENCES
Aird, R. E., Cummings, J., Ritchie,
A. A., Muir, M., Morris, R. E.,
Chen, H., et al. (2002). In vitro and
in vivo activity and cross resistance
profiles of novel ruthenium(II)
organometallic arene complexes
in human ovarian cancer. Br.
J. Cancer 86, 1652–1657. doi:
10.1038/sj.bjc.6600290
Bennett, M. A., Huang, T. N.,
Matheson, T. W., and Smith,
A. K. (1982). (η6-Hexa
methylbenzene)ruthenium com-
plexes. Inorg. Synth. 21, 74–78. doi:
10.1002/9780470132524.ch16
Bennett, M. A., and Smith, A. K.
(1974). Arene ruthenium(II) com-
plexes formed by dehydrogenation
by cyclohexadienes with ruthe-
nium(III) trichloride. J. Chem.
Soc. Dalton Trans. 2, 233–241. doi:
10.1039/dt9740000233
Berger, I., Hanif, M., Nazarov, A.
A., Hartinger, C. G., John, R. O.,
Kuznetsov, M. L., et al. (2008).
In vitro anticancer activity and
biologically relevant metabolization
of organometallic ruthenium com-
plexes with carbohydrate-based lig-
ands. Chem. Eur. J. 14, 9046–9057.
doi: 10.1002/chem.200801032
Casini, A., Gabbiani, C., Sorrentino,
F., Rigobello, M. P., Bindoli, A.,
Geldbach, T. J., et al. (2008).
Emerging Protein Targets for
AnticancerMetallodrugs: Inhibition
of Thioredoxin Reductase and
Cathepsin B by Antitumor
Ruthenium(II)-Arene Compounds.
J. Med. Chem. 51, 6773–6781. doi:
10.1021/jm8006678
Chen, H., Parkinson, J. A., Morris, R.
E., and Sadler, P. J. (2003). Highly
Selective Binding of Organometallic
Ruthenium Ethylenediamine
Complexes to Nucleic Acids: Novel
Recognition Mechanisms. J. Am.
Chem. Soc. 125, 173–186. doi:
10.1021/ja027719m
Dyson, P. J. (2007). Systematic design
of a targeted organometallic
antitumor drug in pre-clinical
development. Chimia 61,
698–703. doi: 10.2533/chimia.
2007.698
Egger, A. E., Rappel, C., Jakupec,
M. A., Hartinger, C. G., Heffeter,
P., and Keppler, B. K. (2009).
Development of an experimental
protocol for uptake studies of metal
compounds in adherent tumor cells.
J. Anal. At. Spectrom. 24, 51–61. doi:
10.1039/b810481f
Fricker, S. P. (2010). Cysteine pro-
teases as targets for metal-based
drugs. Metallomics 2, 366–377. doi:
10.1039/b924677k
Frlan, R., and Gobec, S. (2006).
Inhibitors of cathepsin B. Curr.
Med. Chem. 13, 2309–2327. doi:
10.2174/092986706777935122
Gasser, G., Ott, I., and Metzler-Nolte,
N. (2011). Organometallic anti-
cancer compounds. J. Med. Chem.
54, 3–25. doi: 10.1021/jm100020w
Gottschaldt, M., and Schubert, U. S.
(2009). Prospects of metal com-
plexes peripherally substituted with
sugars in biomedicinal applications.
Chem. Eur. J. 15, 1548–1557. doi:
10.1002/chem.200802013
Habtemariam, A., Melchart, M.,
Fernandez, R., Parsons, S., Oswald,
I. D. H., Parkin, A., et al. (2006).
Structure-Activity Relationships
for Cytotoxic Ruthenium(II) Arene
Complexes Containing, N, N-, N,
O-, and O, O-Chelating Ligands.
J. Med. Chem. 49, 6858–6868. doi:
10.1021/jm060596m
Hanif, M., Meier, S. M., Kandioller, W.,
Bytzek, A., Hejl, M., Hartinger, C.
G., et al. (2011). From hydrolytically
labile to hydrolytically stable RuII-
arene anticancer complexes with
carbohydrate-derived co-ligands.
J. Inorg. Biochem. 105, 224–231. doi:
10.1016/j.jinorgbio.2010.10.004
Hanif, M., Nazarov, A. A.,
and Hartinger, C. G.
(2012a). Synthesis of [RuII(η6-
p-cymene)(PPh3)(L)Cl]PF6 com-
plexes with carbohydrate-derived
phosphites, imidazole or indazole
co-ligands. Inorg. Chim. Acta 380,
211–215. doi: 10.1016/j.ica.2011.
10.007
Hanif, M., Nazarov, A. A., Legin, A.,
Groessl, M., Arion, V. B., Jakupec,
M. A., et al. (2012b). Maleimide-
functionalised organoruthenium
anticancer agents and their binding
to thiol-containing biomolecules.
Chem. Commun. 48, 1475–1477.
doi: 10.1039/c1cc14713g
Hanif, M., Nazarov, A. A., Hartinger,
C. G., Kandioller, W., Jakupec,
M. A., Arion, V. B., et al.
(2010a). Osmium(II)- versus
ruthenium(II)-arene carbohydrate-
based anticancer compounds:
similarities and differences.
Dalton Trans. 39, 7345–7352.
doi: 10.1039/c003085f
Hanif, M., Schaaf, P., Kandioller, W.,
Hejl, M., Jakupec, M. A., Roller,
A., et al. (2010b). Influence of
the arene ligand and the leaving
group on the anticancer activity
of (thio)maltol ruthenium(II)-(η6-
arene) complexes. Aust. J. Chem. 63,
1521–1528. doi: 10.1071/CH10232
Hartinger, C. G., and Dyson, P.
J. (2009). Bioorganometallic
Chemistry - From Teaching
Paradigms to Medicinal
Application. Chem. Soc. Rev. 38,
391–401. doi: 10.1039/b707077m
Hartinger, C. G., Metzler-Nolte,
N., and Dyson, P. J. (2012).
Challenges and Opportunities
in the Development of
Organometallic Anticancer Drugs.
Organometallics 31, 5677–5685. doi:
10.1021/om300373t
Hartinger, C. G., Nazarov, A. A., Ashraf,
S. M., Dyson, P. J., and Keppler,
B. K. (2008). Carbohydrate-Metal
Complexes and their Potential
as Anticancer Agents. Curr.
Med. Chem. 15, 2574–2591. doi:
10.2174/092986708785908978
Kandioller, W., Kurzwernhart, A.,
Hanif, M., Meier, S. M., Henke,
H., Keppler, B. K., et al. (2011).
Pyrone derivatives and met-
als: From natural products to
metal-based drugs. J. Organomet.
Chem. 696, 999–1010. doi:
10.1016/j.jorganchem.2010.11.010
Kochetkov, N. K., Nifant’ev, E. E.,
Koroteev, M. P., Zhane, Z. K., and
Borisenko, A. A. (1976). Synthesis
and stereochemistry of 6-deoxy-
6-halo-D-glucofuranose cyclic
phosphates. Carbohydr. Res. 47,
221–231. doi: 10.1016/S0008-
6215(00)84187-7
Mendoza-Ferri, M. G., Hartinger,
C. G., Nazarov, A. A., Eichinger,
R. E., Jakupec, M. A., Severin,
K., et al. (2009). Influence of the
arene ligand, the number and
type of metal centers, and the
leaving group on the in vitro
antitumor activity of polynu-
clear organometallic compounds.
Organometallics 28, 6260–6265. doi:
10.1021/om900715j
Mohamed, M. M., and Sloane, B.
F. (2006). Cysteine cathepsins:
multifunctional enzymes in cancer.
Nat. Rev. Cancer 6, 764–775. doi:
10.1038/nrc1949
Mura, P., Camalli, M., Casini, A.,
Gabbiani, C., and Messori,
L. (2010). Trans–cis–cis-
[RuCl2(DMSO)2(2-amino-5-
methyl-thiazole)2], (PMRu52),
a novel ruthenium(II) com-
pound acting as a strong
inhibitor of cathepsin B. J. Inorg.
Biochem. 104, 111–117. doi:
10.1016/j.jinorgbio.2009.10.002
Nazarov, A. A., Risse, J., Ang, W.
H., Schmitt, F., Zava, O., Ruggi,
A., et al. (2012). Anthracene-
Tethered Ruthenium(II) Arene
Complexes as Tools To Visualize
the Cellular Localization of Putative
Organometallic Anticancer
Compounds. Inorg. Chem. 51,
3633–3639. doi: 10.1021/ic202530j
Peacock, A. F. A., and Sadler, P. J.
(2008). Medicinal organometallic
chemistry: designing metal arene
complexes as anticancer agents.
Chem. Asian J. 3, 1890–1899. doi:
10.1002/asia.200800149
Scolaro, C., Bergamo, A., Brescacin,
L., Delfino, R., Cocchietto,
M., Laurenczy, G., et al.
(2005). In vitro and in vivo
evaluation of ruthenium(II)-
Arene PTA complexes. J. Med.
Chem. 48, 4161–4171. doi:
10.1021/jm050015d
Scolaro, C., Hartinger, C. G., Allardyce,
C. S., Keppler, B. K., and Dyson,
P. J. (2008). Hydrolysis study
of the bifunctional antitumor
compound RAPTA-C, [Ru(η6-
p-cymene)Cl2(pta)]. J. Inorg.
Biochem. 102, 1743–1748. doi:
10.1016/j.jinorgbio.2008.05.004
Wu, B., Ong, M. S., Groessl, M.,
Adhireksan, Z., Hartinger, C.
G., Dyson, P. J., et al. (2011). A
Ruthenium Antimetastasis Agent
Forms Specific Histone Protein
Adducts in the Nucleosome Core.
Chem. Eur. J. 17, 3562–3566. doi:
10.1002/chem.201100298
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 31 July 2013; accepted: 10
October 2013; published online: 31
October 2013.
Citation: Hanif M, Meier SM, Nazarov
AA, Risse J, Legin A, Casini A, Jakupec
MA, Keppler BK and Hartinger CG
(2013) Influence of the π-coordinated
arene on the anticancer activity of ruthe-
nium(II) carbohydrate organometallic
complexes. Front. Chem. 1:27. doi:
10.3389/fchem.2013.00027
This article was submitted to Inorganic
Chemistry, a section of the journal
Frontiers in Chemistry.
Copyright © 2013 Hanif, Meier,
Nazarov, Risse, Legin, Casini, Jakupec,
Keppler and Hartinger. This is an
open-access article distributed under
the terms of the Creative Commons
Attribution License (CC BY). The use,
distribution or reproduction in other
forums is permitted, provided the orig-
inal author(s) or licensor are credited
and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permit-
ted which does not comply with these
terms.
www.frontiersin.org October 2013 | Volume 1 | Article 27 | 7
